Oxtexs, an Oxford, UK-based developer of novel and intelligent hydrogel self-inflating tissue expanders, raised £500k in seed funding.
The company’s products will be used in scar reconstruction, and for the treatment of congenital craniofacial conditions and limb deformities. These devices are designed to allow surgeons to accurately and predictably control the direction, the timing, and rate of in vivo expansion, reducing the risk of soft tissue damage and associated complications.
Incorporated in Spring 2011 as a spinout from the University of Oxford and led by CEO David Jackson, Oxtexs is currently establishing clean-room manufacturing facilities to scale-up production, and is in the process of setting-up clinical trials.
The company also appointed Nicholas Edwards as Chairman.
Dr Edwards joined Andersen Consulting (now Accenture) in 1986 and spent eighteen years there, including eight as a partner. He is also Chairman of MedInnovate, and Kinapse, and is an investor and supporter of several life science startups.
FinSMEs
08/09/2011